Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 10:44AM ET
0.1865
Dollar change
-0.0035
Percentage change
-1.84
%
Index- P/E- EPS (ttm)-1.79 Insider Own9.16% Shs Outstand47.78M Perf Week-1.84%
Market Cap8.91M Forward P/E- EPS next Y-0.35 Insider Trans0.00% Shs Float43.41M Perf Month-23.85%
Income-23.42M PEG- EPS next Q-0.11 Inst Own5.94% Short Float0.98% Perf Quarter-33.63%
Sales0.00M P/S- EPS this Y86.50% Inst Trans5.58% Short Ratio0.23 Perf Half Y20.32%
Book/sh-0.23 P/B- EPS next Y56.79% ROA-168.70% Short Interest0.42M Perf Year-86.68%
Cash/sh0.07 P/C2.53 EPS next 5Y- ROE-1191.31% 52W Range0.13 - 1.66 Perf YTD-86.19%
Dividend Est.- P/FCF- EPS past 5Y18.87% ROI- 52W High-88.77% Beta1.77
Dividend TTM- Quick Ratio0.40 Sales past 5Y0.00% Gross Margin- 52W Low45.59% ATR (14)0.02
Dividend Ex-Date- Current Ratio0.40 EPS Y/Y TTM77.74% Oper. Margin- RSI (14)34.13 Volatility11.02% 10.11%
Employees80 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q96.89% Payout- Rel Volume0.42 Prev Close0.19
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsNov 12 Avg Volume1.83M Price0.19
SMA20-13.64% SMA50-20.61% SMA200-56.83% Trades Volume176,061 Change-1.84%
Date Action Analyst Rating Change Price Target Change
May-18-21Initiated BTIG Research Buy $11
Oct-02-20Initiated B. Riley FBR Buy $9
Nov-20-19Initiated Cantor Fitzgerald Overweight $7
Aug-13-19Initiated H.C. Wainwright Buy $7
Jun-21-19Initiated Cantor Fitzgerald Overweight $7
Dec-21-17Initiated Oppenheimer Outperform $18
Nov-12-24 08:30AM
Nov-08-24 06:36AM
Nov-07-24 08:30AM
Oct-26-24 05:20PM
Oct-24-24 02:10PM
08:00AM Loading…
Jun-28-24 08:00AM
Jun-21-24 04:01PM
Jun-20-24 05:26PM
08:00AM
07:28AM
Jun-18-24 10:22AM
07:37AM
07:30AM
Jun-17-24 01:28PM
01:03PM
12:07PM Loading…
12:07PM
08:30AM
May-22-24 08:04AM
07:23AM
May-16-24 10:53AM
May-02-24 04:01PM
Apr-30-24 06:03AM
Apr-29-24 08:00PM
Mar-28-24 04:05PM
09:00AM
Mar-11-24 04:05PM
Mar-07-24 07:30AM
Jan-11-24 08:30AM
Dec-11-23 08:30AM
Nov-14-23 04:05PM
09:28AM Loading…
Nov-02-23 09:28AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
09:00AM
Sep-07-23 08:15AM
Aug-16-23 08:00AM
Aug-14-23 04:05PM
04:01PM
Aug-03-23 08:00AM
Jul-31-23 08:30AM
Jul-06-23 08:00AM
Jun-15-23 04:01PM
Jun-13-23 01:49PM
Jun-12-23 09:55AM
08:00AM
May-26-23 09:55AM
May-18-23 08:03AM
May-15-23 04:01PM
May-12-23 04:05PM
May-11-23 04:03PM
Apr-03-23 12:15PM
Mar-30-23 04:10PM
Mar-29-23 04:15PM
Mar-28-23 08:30AM
Jan-17-23 08:15AM
Dec-19-22 08:30AM
Nov-14-22 04:05PM
Oct-27-22 08:00AM
Oct-06-22 08:30AM
Sep-08-22 08:00AM
Sep-02-22 09:55AM
Aug-11-22 04:05PM
Jul-27-22 08:00AM
Jul-17-22 08:21AM
Jun-22-22 08:00AM
Jun-13-22 08:00AM
May-19-22 03:23PM
08:45AM
May-12-22 04:05PM
10:38AM
May-03-22 08:00AM
Apr-25-22 08:00AM
Apr-21-22 08:30AM
Apr-13-22 10:00AM
Apr-04-22 08:00AM
Apr-01-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 08:30AM
Mar-09-22 08:00AM
Mar-08-22 09:00AM
Feb-15-22 07:30AM
Feb-08-22 08:30AM
Feb-07-22 09:11AM
Jan-25-22 07:10AM
Jan-24-22 05:00PM
Jan-07-22 02:05PM
Jan-05-22 08:30AM
Dec-16-21 08:30AM
Dec-13-21 09:00AM
Dec-09-21 08:30AM
Dec-06-21 07:30AM
Nov-12-21 08:05AM
Nov-10-21 08:00AM
Nov-09-21 09:02AM
Nov-04-21 09:24AM
Nov-01-21 10:19AM
08:30AM
Oct-06-21 10:28AM
Oct-04-21 09:57AM
Sep-30-21 08:30AM
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.